Citicoline
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Citicoline
- Molecular weight
- 488.33
- Structure (SMILES)
- C[N+](C)(C)CCOP(=O)(O)OP(=O)([O-])OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O
- cdp choline
- Cdp-choline
- CDP-choline
- CDP-Choline
- citicolina
- Citicolina
- citicoline
- Citicoline
- citicoline [INN]
- CITICOLINE [JAN]
- CITICOLINE [MART.]
- CITICOLINE [MI]
- CITICOLINE [USP-RS]
- CITICOLINE [VANDF]
- Citicoline [WHO-DD]
- citicoline inn
- citicoline jan
- citicoline mart
- citicoline mi
- citicoline usp rs
- citicoline vandf
- citicoline who dd
- cytidine 5 diphosphate choline
- cytidine 5 diphosphocholine
- cytidine 5 trihydrogen diphosphate p 2 trimethylammonio ethyl ester inner salt
And 10 more, listed on the interactive page.
- ATC classification codes
- N06BX06
Sources for recorded values
- CAS registry numbers
- 987-78-0
- ChEMBL ID
- CHEMBL1231700
- InChIKey
- RZZPDXZPRHQOCG-OJAKKHQRSA-N
- RxNorm IDs (RxCUI)
- 997602
- FDA ingredient codes (UNII)
- 536BQ2JVC7
- 13804
- 11583971
- 76963096
- First in class
- No
- Orphan designation
- No
- Condition
- Stroke
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Attention Deficit Disorder with Hyperactivity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003888
- Subject identifier
- D001289
- Condition
- Glaucoma, Open-Angle
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004190
- Subject identifier
- D005902
- Condition
- Amphetamine-Related Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004701
- Subject identifier
- D019969
- Condition
- Marijuana Abuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007191
- Subject identifier
- D002189
- Condition
- Ischemic Stroke
- Highest recorded phase
- 3
- Condition identifier
- HP:0002140
- Subject identifier
- D000083242
- Condition
- Cerebral Infarction
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002679
- Subject identifier
- D002544
- Condition
- Brain Ischemia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005299
- Subject identifier
- D002545
- Condition
- Alcoholism
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007079
- Subject identifier
- D000437
- Condition
- Brain Injuries
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0043510
- Subject identifier
- D001930
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001072
- Condition identifier
- EFO_0003888
- Condition identifier
- EFO_0004190
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004701
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005772
- Condition identifier
- EFO_0007191
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009444
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009965
- Highest recorded phase
- 3
- Condition identifier
- HP_0002140
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002009
- Condition identifier
- MONDO_0002679
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004456
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004985
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005041
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005090
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005186
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005299
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005338
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005419
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005689
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006663
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007079
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007743
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0010382
- Highest recorded phase
- 2
And 3 more, listed on the interactive page.
- Event
- apraxia
- Reports
- 4
- Reporting signal score
- 25.3635
- Event
- cognitive disorder
- Reports
- 5
- Reporting signal score
- 17.5726
- Event
- disorientation
- Reports
- 4
- Reporting signal score
- 12.9851
- Event
- drug interaction
- Reports
- 15
- Reporting signal score
- 48.926
- Event
- hepatitis
- Reports
- 3
- Reporting signal score
- 9.36954
- Event
- hyperreflexia
- Reports
- 4
- Reporting signal score
- 20.9693
- Event
- myoclonus
- Reports
- 4
- Reporting signal score
- 16.5729
- Event
- neuroleptic malignant syndrome
- Reports
- 7
- Reporting signal score
- 32.7976
- NCT00158249
- NCT00331890
- NCT00545662
- NCT01591759
- NCT00950352
- NCT02823106
- NCT05154903
- NCT06210646
- NCT03181646
- NCT05710198
- NCT05870111
- NCT05881135
- Hydrogen bond acceptors
- 13
- Hydrogen bond donors
- 4
- Polar surface area
- 215.72
- Calculated partition coefficient (ALogP)
- -2.23
- Calculated partition coefficient (XLogP)
- -4
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 10
- Heavy atoms
- 31
- Molecular formula
- C14H26N4O11P2
- Monoisotopic mass
- 488.10733165
- Natural product
- Yes
- Recorded assays
- 4
- Active assays
- 0
- Nootropic Agents
Related records
Trials (32)
- A Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence
- A Pilot Trial of Citicoline in Individuals With Mild Traumatic Brain Injury (mTBI)
- CDP-Choline and Working Memory After TBI: A Neuroimaging Study
- CDP-choline Treatment in ATS Users
- Citicoline and Omega-3 Fatty Acid Effects in Veterans With Traumatic Brain Injury (TBI)
- Citicoline as Neuroprotector in Neonates Exposed to Hypoxia
- Citicoline as Neuroprotector in Preterm
- Citicoline Concentration in Human Vitreous
- Citicoline for Alcohol Dependence
- Citicoline for Bipolar 1 Disorder and Cocaine Dependence
- Citicoline in Ischemic Stroke
- Citicoline in Ischemic Stroke, a Randomized Trial
- Citicoline in Youth Alcohol Use Disorder
- Citicoline Treatment of Methamphetamine Dependence
- Citicoline, Creatine, and Omega-3 Effects in Middle Age Women
- Cognizin Citicoline Dosing in a Healthy Adolescent Male Population
- Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy
- Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma
- Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
- Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
In development for (11)
- Alcohol dependence Phase 2
- Attention deficit-hyperactivity disorder Phase 3
- Brain injury Phase 3
- Brain ischemia Phase 3
- Cannabis dependence Phase 2
- Cerebral infarction Phase 3
- COVID-19 Phase 1
- Ischemic stroke Phase 3
- Methamphetamine dependence Phase 3
- Open-angle glaucoma Phase 3
- Stroke disorder Phase 3